About one in five patients with cancer who undergo genetic testing are incidentally found to have mutations in their blood called clonal hematopoiesis of indeterminate potential (CHIP). A study by Vanderbilt Health researchers reveals that it puts them at increased risk for heart disease following cancer treatment.
This article was originally published on MedicalXpress.com

